Seasonal Influenza Vaccine Effectiveness, 2015-2016
Age | Number | % Total |
---|---|---|
6 months-8 years | 1,526 | 22 |
9-17 years | 858 | 13 |
18-49 years | 2,456 | 36 |
50-64 years | 1,201 | 18 |
65+ years | 838 | 12 |
Gender | Number | % Total |
---|---|---|
Male | 2,833 | 41 |
Female | 4,046 | 59 |
Race | Number | % Total |
---|---|---|
White, non-Hispanic | 5,152 | 75 |
Black, non-Hispanic | 559 | 8 |
Hispanic | 553 | 8 |
Other, non-Hispanic | 588 | 8 |
On This Page
- Patients by Age
- Patients by Gender
- Patients by Race
- Influenza Virus Type And Subtype Among Influenza-Positive Patients
- Vaccine Effectiveness for all Vaccine Types Against influenza A or B viruses
- Vaccine Effectiveness for all Vaccine Types Against Influenza A (H1N1) viruses
- Vaccine Effectiveness for all Vaccine Types Against All Vaccine Types, Influenza B Viruses
- Influenza vaccine effectiveness for all vaccine types, Against Influenza B Virus lineage
- Influenza vaccine effectiveness for Inactivated Influenza Vaccine in children, against influenza A or B viruses
- Influenza vaccine effectiveness for Live Attenuated Influenza Vaccines in Children, Against Influenza A or B Viruses
Coinfections present include: 5 cases coinfected with Influenza A (H3N2) and Influenza B Yamagata; 1 case coinfected with Influenza A (H3N2) and Influenza B Yamagata (lineage not determined); 1 case coinfected with Influenza A (not subtyped) and Influenza B Yamagata; 3 cases coinfected with Influenza B Yamagata and Influenza B/Victoria
Top of Page Top of Page Top of Page- Page last reviewed: September 12, 2018
- Page last updated: September 12, 2018
- Content source:
- Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD)
- Page maintained by: Office of the Associate Director for Communication, Digital Media Branch, Division of Public Affairs